Valery Krasnoperov
Chief Tech/Sci/R&D Officer bei HALO COLLECTIVE INC.
Profil
Valery Krasnoperov is currently the Chief Scientific Officer at Halo Collective, Inc. Prior to this, he worked as the Director of Research & Development at VasGene Therapeutics, Inc. He also worked as a Research Scientist at New York University and The University of Nottingham.
Aktive Positionen von Valery Krasnoperov
| Unternehmen | Position | Beginn |
|---|---|---|
| HALO COLLECTIVE INC. | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Valery Krasnoperov
| Unternehmen | Position | Ende |
|---|---|---|
| New York University | Corporate Officer/Principal | - |
| The University of Nottingham | Corporate Officer/Principal | - |
VasGene Therapeutics, Inc.
 VasGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services VasGene Therapeutics, Inc. developed therapeutics based on vascular biology. Its products included target signal transduction pathways common to cancer cells and endothelial cells, resulting in anti-cancer agents with multiple modes of action and inhibition of tumor cell growth, anti-angiogenesis and prevention of tumor cell metastasis. The company was founded by Raymond A. Mirra Jr. and Parkash Gill in 1999 and was headquartered in Oak Park, CA. | Chief Tech/Sci/R&D Officer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HALO COLLECTIVE INC. | Process Industries |
| Private Unternehmen | 1 |
|---|---|
VasGene Therapeutics, Inc.
VasGene Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services VasGene Therapeutics, Inc. developed therapeutics based on vascular biology. Its products included target signal transduction pathways common to cancer cells and endothelial cells, resulting in anti-cancer agents with multiple modes of action and inhibition of tumor cell growth, anti-angiogenesis and prevention of tumor cell metastasis. The company was founded by Raymond A. Mirra Jr. and Parkash Gill in 1999 and was headquartered in Oak Park, CA. | Commercial Services |
